logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Boehringer Ingelheim Pharmaceuticals, Inc. drugs

    FiltersReset Filters
    24 results

    • adalimumab - adbm - adalimumab - adbm

      (Adalimumab-Adbm)
      Boehringer Ingelheim Pharmaceuticals, Inc.

    • aptivus - tipranavir capsule, liquid filled

      (Tipranavir)
      Boehringer Ingelheim Pharmaceuticals, Inc.

    • atrovent hfa - ipratropium bromide aerosol, metered

      (Ipratropium Bromide)
      Boehringer Ingelheim Pharmaceuticals, Inc.

    • combivent respimat

      (ipratropium bromide and albuterol)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: COMBIVENT RESPIMAT is indicated for patients with chronic obstructive pulmonary disease (COPD) who have ongoing bronchospasm and require an additional bronchodilator while using a regular aerosol bronchodilator. It combines ipratropium bromide and albuterol sulfate for enhanced respiratory relief.

    • cyltezo

      (adalimumab-adbm)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: CYLTEZO is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients aged 2 and older.

    • gilotrif

      (afatinib)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: GILOTRIF is indicated for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with non-resistant EGFR mutations, and for previously treated metastatic squamous NSCLC progressing after platinum-based chemotherapy. Its safety and efficacy in resistant EGFR mutations are not established.

    • glyxambi

      (empagliflozin and linagliptin)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: GLYXAMBI, a combination of empagliflozin and linagliptin, is indicated to improve glycemic control in adults with type 2 diabetes mellitus alongside diet and exercise. Empagliflozin also reduces cardiovascular death risk in patients with type 2 diabetes and existing cardiovascular disease. It is not suitable for type 1 diabetes or certain conditions.

    • hernexeos - zongertinib tablet, film coated

      (Zongertinib)
      Boehringer Ingelheim Pharmaceuticals, Inc.

    • jardiance

      (Empagliflozin)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: JARDIANCE is indicated for reducing the risk of cardiovascular death and hospitalization in adults with heart failure, chronic kidney disease, and type 2 diabetes with established cardiovascular disease. It also aids glycemic control as an adjunct to diet and exercise in patients aged 10 and older with type 2 diabetes.

    • jentadueto

      (linagliptin and metformin hydrochloride)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: JENTADUETO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not recommended for patients with type 1 diabetes or a history of pancreatitis, as its effects in these populations are unclear.